United Therapeutics Corporation
UTHR
NGS
Sector: Healthcare
Industry: Biotechnology
211.08
USD
5.19
(2.52%)
Optionable: Yes Market Cap: 9,371 M 90-day average vol: 397,104
Previous close: 205.89 Open: 208.01 Bid: 218.13 Ask: 218.13
52 week range
158.38 245.48
Last updated: Thursday 29th September 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 5.24 |
Price per Book TTM ($) | 2.14 |
PE Ratio (TTM) | 15.40 |
Book Value per Share ($) | 94.88 |
5 Year PE Range-35.5 |
Returns
7 Day Return | 2.68% | |
1 Month Return | -2.95% | |
3 Month Return | -10.42% | |
1 Year Return | 12.48% | |
3 Year Return | 164.68% | |
5 Year Return | 80.12% | |
YTD Return | -2.31% |
Risk
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 43.85 |
14 Day SMA ($) | 213.25 |
14 Day EMA ($) | 211.99 |
Money Flow Index | 50.38 |
Average True Range | 6.40 |
50 Day SMA ($) | 220.57 |
200 Day SMA ($) | 205.93 |
ADX | 15.26 |
MACD | -4.29 |
Growth
Free Cash Flow QoQ Growth | -60.03% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | -51.79% |
Revenue QoQ Growth | 1.08% |
EPS YoY Growth | 0.00% |
Profitability
News
Financials
UTHR Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 916 M | 1,117 M | 1,289 M | 1,466 M | 1,599 M | 1,725 M | 1,628 M | 1,449 M | 1,483 M | 1,686 M |
| Cost of sales | 88 M | 95 M | 88 M | 34 M | 41 M | 75 M | 163 M | 72 M | 58 M | 73 M |
| Gross operating profit | 787 M | 976 M | 1,154 M | 1,392 M | 1,526 M | 1,620 M | 1,429 M | 1,331 M | 1,375 M | 1,563 M |
| Selling Gen & administrative expense | 202 M | 394 M | 381 M | 453 M | 317 M | 330 M | 266 M | 336 M | 424 M | 467 M |
| Research & development expense | 173 M | 299 M | 243 M | 245 M | 148 M | 265 M | 358 M | 1,183 M | 358 M | 540 M |
| Operating income | 422 M | 292 M | 539 M | 699 M | 1,062 M | 1,025 M | 805 M | -188 M | 594 M | 556 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 36 M | 4 M | 4 M | 350 M | -1 M | -257 M | -61 M | 23 M | 40 M | 40 M |
| Pre-tax Income (EBT) | 441 M | 279 M | 525 M | 1,044 M | 1,060 M | 770 M | 759 M | -165 M | 639 M | 594 M |
| Income taxes | 136 M | 104 M | 185 M | 393 M | 347 M | 352 M | 170 M | -60 M | 124 M | 118 M |
| Net income from total operations | 304 M | 175 M | 340 M | 652 M | 714 M | 418 M | 589 M | -104 M | 515 M | 476 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | 304 M | 175 M | 340 M | 652 M | 714 M | 418 M | 589 M | -104 M | 515 M | 476 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | 304 M | 175 M | 340 M | 652 M | 714 M | 418 M | 589 M | -104 M | 515 M | 476 M |
| Depreciation | 32 M | 36 M | 37 M | 35 M | 32 M | 31 M | 36 M | 46 M | 50 M | 50 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | 484 M | 328 M | 575 M | 1,082 M | 1,096 M | 810 M | 809 M | -75 M | 712 M | 662 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | 5.84 | 3.49 | 7.06 | 14.17 | 16.29 | 9.5 | 13.54 | -2.39 | 11.65 | 10.6 |
| Diluted EPS total | 5.71 | 3.28 | 6.28 | 12.72 | 15.25 | 9.31 | 13.39 | -2.39 | 11.54 | 10.06 |
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONSGet started today